Published in J Virol on January 01, 1992
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 7.76
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol (2002) 5.82
Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A (1996) 4.76
Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol (1997) 2.91
Identification of linear DNA sequences that specifically bind the adeno-associated virus Rep protein. J Virol (1994) 2.52
Subcellular compartmentalization of adeno-associated virus type 2 assembly. J Virol (1997) 2.31
Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol (1997) 2.19
In vitro replication of adeno-associated virus DNA. J Virol (1994) 2.09
Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. J Virol (1999) 1.94
The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J Virol (1997) 1.89
Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers. J Virol (1996) 1.86
Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol (2004) 1.67
Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol (1994) 1.63
Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells. J Virol (1992) 1.52
Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J Virol (2000) 1.37
The cellular transcription factor SP1 and an unknown cellular protein are required to mediate Rep protein activation of the adeno-associated virus p19 promoter. J Virol (1997) 1.34
Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. J Virol (2006) 1.33
A beta-stranded motif drives capsid protein oligomers of the parvovirus minute virus of mice into the nucleus for viral assembly. J Virol (2000) 1.32
Adeno-associated virus replication induces a DNA damage response coordinated by DNA-dependent protein kinase. J Virol (2009) 1.24
In vitro packaging of adeno-associated virus DNA. J Virol (1998) 1.22
Adeno-associated virus interactions with B23/Nucleophosmin: identification of sub-nucleolar virion regions. Virology (2006) 1.21
Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes. J Virol (1999) 1.20
Inhibition of PrKX, a novel protein kinase, and the cyclic AMP-dependent protein kinase PKA by the regulatory proteins of adeno-associated virus type 2. Mol Cell Biol (1998) 1.20
The Rep protein of adeno-associated virus type 2 interacts with single-stranded DNA-binding proteins that enhance viral replication. J Virol (2004) 1.17
Identification of cellular proteins that interact with the adeno-associated virus rep protein. J Virol (2008) 1.12
Recombinant adeno-associated viral vectors are deficient in provoking a DNA damage response. J Virol (2008) 1.00
Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression. J Virol (2003) 0.98
Impact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging. J Virol (2006) 0.96
Spatial and temporal organization of adeno-associated virus DNA replication in live cells. J Virol (2004) 0.96
Purification of host cell enzymes involved in adeno-associated virus DNA replication. J Virol (2007) 0.96
Adeno-associated virus and adenovirus coinfection induces a cellular DNA damage and repair response via redundant phosphatidylinositol 3-like kinase pathways. Virology (2009) 0.87
A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J Virol (2002) 0.87
Charge-to-alanine mutagenesis of the adeno-associated virus type 2 Rep78/68 proteins yields temperature-sensitive and magnesium-dependent variants. J Virol (1999) 0.86
Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes. J Virol (2002) 0.84
Adeno-associated virus type 2 modulates the host DNA damage response induced by herpes simplex virus 1 during coinfection. J Virol (2011) 0.81
Viral and Cellular Components of AAV2 Replication Compartments. Open Virol J (2013) 0.77
The large Rep protein of adeno-associated virus type 2 is polyubiquitinated. J Gen Virol (2011) 0.76
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol (1986) 55.34
A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes. Proc Natl Acad Sci U S A (1985) 46.59
Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol (1989) 6.69
The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell (1990) 5.98
Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol (1984) 5.89
Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A (1982) 5.73
Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell (1983) 5.27
Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol (1984) 4.98
The intranuclear location of a herpes simplex virus DNA-binding protein is determined by the status of viral DNA replication. Cell (1984) 4.90
A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol (1987) 4.57
Replacement of the fip gene of Escherichia coli by an inactive gene cloned on a plasmid. J Bacteriol (1984) 3.83
Factors that bind to adeno-associated virus terminal repeats. J Virol (1989) 3.56
In vitro resolution of covalently joined AAV chromosome ends. Cell (1990) 3.24
Identification of the trans-acting Rep proteins of adeno-associated virus by antibodies to a synthetic oligopeptide. J Virol (1986) 3.09
Spliced adenovirus-associated virus RNA. Proc Natl Acad Sci U S A (1979) 2.99
Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication. Virology (1989) 2.91
Mapping of the 5' termini of two adeno-associated virus 2 RNAs in the left half of the genome. J Virol (1982) 2.75
Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature (1991) 2.75
Evidence for covalent attachment of the adeno-associated virus (AAV) rep protein to the ends of the AAV genome. J Virol (1990) 2.62
Identification of nuclear proteins that specifically interact with adeno-associated virus type 2 inverted terminal repeat hairpin DNA. J Virol (1989) 2.60
Replication of adeno-associated virus DNA. Complementation of naturally occurring rep- mutants by a wild-type genome or an ori- mutant and correction of terminal palindrome deletions. J Mol Biol (1984) 2.51
Transcripts of the adeno-associated virus genome: mapping of the major RNAs. J Virol (1980) 2.42
Sequences required for coordinate induction of adeno-associated virus p19 and p40 promoters by Rep protein. J Virol (1991) 2.31
Characterization of adeno-associated virus rep proteins in human cells by antibodies raised against rep expressed in Escherichia coli. Virology (1987) 1.85
Identification of two nuclear subclasses of the adenovirus type 5-encoded DNA-binding protein. J Virol (1986) 1.69
Transcripts of the adenovirus-associated virus genome: multiple polyadenylated RNAs including a potential primary transcript. J Virol (1980) 1.63
Adeno-associated virus rep protein synthesis during productive infection. J Virol (1989) 1.54
Localization of the herpes simplex virus type 1 65-kilodalton DNA-binding protein and DNA polymerase in the presence and absence of viral DNA synthesis. J Virol (1990) 1.38
Interactions of minute virus of mice and adenovirus with host nucleoli. J Virol (1989) 1.37
Differential distribution of the adenovirus E1A proteins and colocalization of E1A with the 70-kilodalton cellular heat shock protein in infected cells. J Virol (1988) 1.33
Maturation of parvovirus LuIII in a subcellular system. I. Optimal conditions for in vitro synthesis and encapsidation of viral DNA. J Gen Virol (1983) 1.31
Adeno-associated virus helper activity of adenovirus DNA binding protein. J Virol (1982) 1.14
Proteins of viral and cellular origin bind to the Aleutian disease virus (ADV) DNA 3'-terminal hairpin: presentation of a scheme for encapsidation of ADV DNA. J Virol (1990) 1.00
Immunological analysis of 140-kDa adenovirus-encoded DNA polymerase in adenovirus type 2-infected HeLa cells using antibodies raised against the protein expressed in Escherichia coli. Virology (1987) 0.95
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther (1999) 7.96
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 7.76
Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A (1990) 7.06
Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol (1996) 6.43
Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol (1996) 6.22
Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A (1982) 5.73
Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet (1994) 5.49
Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell (1983) 5.27
AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med (1999) 5.26
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther (2003) 4.92
A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol (1987) 4.57
Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther (2001) 4.35
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol (2000) 3.84
Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther (2000) 3.32
In vitro resolution of covalently joined AAV chromosome ends. Cell (1990) 3.24
Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res (1996) 3.03
Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein. J Virol (1993) 2.69
Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J Virol (1997) 2.32
Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol (1997) 2.19
Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 chromosome. J Virol (1987) 2.09
Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther (1998) 2.06
Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci U S A (1992) 1.82
Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology (1999) 1.76
Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood (1994) 1.75
Immune responses to AAV in a phase I study for Canavan disease. J Gene Med (2006) 1.74
Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol (1997) 1.73
The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol Med (2001) 1.69
Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther (2001) 1.65
Rapid purification of covalently closed circular DNAs of bacterial plasmids and animal tumor viruses. Anal Biochem (1980) 1.60
A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol (1997) 1.57
Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther (1998) 1.52
Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol (1999) 1.51
Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther (2011) 1.47
AAV vectors: is clinical success on the horizon? Gene Ther (2000) 1.47
Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today (2000) 1.45
Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest (1994) 1.39
Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J Virol (2000) 1.37
Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J Virol (2000) 1.32
Recombinant adeno-associated virus (rAAV)-mediated expression of a human gamma-globin gene in human progenitor-derived erythroid cells. Proc Natl Acad Sci U S A (1994) 1.28
Adeno-associated viral vectors as gene delivery vehicles. Int J Mol Med (2000) 1.25
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther (2011) 1.24
Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within the AAV terminal repeat. Proc Natl Acad Sci U S A (2001) 1.21
New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat Med (1997) 1.21
Building a better vector: the manipulation of AAV virions. Virology (2000) 1.19
Construction of a recombinant human parvovirus B19: adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B19 hybrid virus. Proc Natl Acad Sci U S A (1989) 1.17
Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: comparison with adenovirus vectors. J Virol (1998) 1.17
Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. Ann Thorac Surg (1996) 1.16
In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther (1998) 1.16
Gene therapy for human hemoglobinopathies. Proc Soc Exp Biol Med (1993) 1.15
The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. Hum Gene Ther (2000) 1.14
Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther (1998) 1.09
Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs. Gene Ther (2012) 1.09
Gene therapy: targeting the myocardium. Heart (2008) 1.06
Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo. Gene Ther (2007) 1.05
Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther (2005) 1.05
NIDDK Workshop on AAV Vectors: Gene Transfer into Quiescent Cells. Hum Gene Ther (1996) 0.98
Kinetics of recombinant adeno-associated virus-mediated gene transfer. J Virol (2000) 0.98
Efficient expression of protein coding genes from the murine U1 small nuclear RNA promoters. Proc Natl Acad Sci U S A (1996) 0.98
Gene transfer in human lymphocytes using a vector based on adeno-associated virus. J Immunother (1991) (1992) 0.98
Delivery of the Cu/Zn-superoxide dismutase gene with adenovirus reduces early alcohol-induced liver injury in rats. Gastroenterology (2001) 0.98
Adeno-associated virus-mediated gene transfer of the heart/muscle adenine nucleotide translocator (ANT) in mouse. Gene Ther (2005) 0.97
Fluorescent viral vectors: a new technique for the pharmacological analysis of gene therapy. Nat Med (1998) 0.97
Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adeno-associated viral vectors. Hum Gene Ther (2009) 0.97
Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res (1997) 0.96
Self-complementary AAV mediates gene targeting and enhances endonuclease delivery for double-strand break repair. Gene Ther (2010) 0.95
Heart failure: a silver bullet to treat heart failure. Gene Ther (2006) 0.95
Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non-human primate after overexpression of GDNF. J Comp Neurol (2009) 0.92
Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat Med (1999) 0.91
Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther (2011) 0.91
Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther (2008) 0.90
The influence of epileptic neuropathology and prior peripheral immunity on CNS transduction by rAAV2 and rAAV5. Gene Ther (2011) 0.90
AAV as a viral vector for human gene therapy. Generation of recombinant virus. Mol Biotechnol (1995) 0.89
AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons. Exp Neurol (2008) 0.88
A small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Ther (2008) 0.87
Cu/Zn-superoxide dismutase gene attenuates ischemia-reperfusion injury in the rat kidney. J Am Soc Nephrol (2001) 0.87
Comparison of the effect of adenoviral delivery of three superoxide dismutase genes against hepatic ischemia-reperfusion injury. Hum Gene Ther (2001) 0.86
Charge-to-alanine mutagenesis of the adeno-associated virus type 2 Rep78/68 proteins yields temperature-sensitive and magnesium-dependent variants. J Virol (1999) 0.86
Site-specific targeting of DNA plasmids to chromosome 19 using AAV cis and trans sequences. Methods Mol Biol (2000) 0.85
Efficient transduction of vascular smooth muscle cells with a translational AAV2.5 vector: a new perspective for in-stent restenosis gene therapy. Gene Ther (2013) 0.83
Three-dimensional multipotent progenitor cell aggregates for expansion, osteogenic differentiation and 'in vivo' tracing with AAV vector serotype 6. Gene Ther (2012) 0.83
Expanding the AAV package. Nat Biotechnol (2000) 0.80
Delivery of Cu/Zn-superoxide dismutase genes with a viral vector minimizes liver injury and improves survival after liver transplantation in the rat. Transplantation (2000) 0.80
Chronic ethanol increases adeno-associated viral transgene expression in rat liver via oxidant and NFkappaB-dependent mechanisms. Hepatology (2000) 0.80
The genetics of adeno-associated virus. Adv Exp Med Biol (1984) 0.79
Methods for adeno-associated virus-mediated gene transfer into muscle. Methods Mol Biol (2001) 0.79
Delivering multiple gene products in the brain from a single adeno-associated virus vector. Gene Ther (2009) 0.78
Efficient gene transfer into primary and immortalized human fetal glial cells using adeno-associated virus vectors: establishment of a glial cell line with a functional CD4 receptor. J Neurovirol (1997) 0.76
Gene therapy for cardiomyocytes, a heart beat away. Gene Ther (2009) 0.76
Vector biophysics: crystal-clear view. Gene Ther (2002) 0.75
Adeno-associated virus vectors for gene transfer into erythroid cells. Curr Top Microbiol Immunol (1996) 0.75
Expression of the human glucocerebrosidase and arylsulfatase A genes in murine and patient primary fibroblasts transduced by an adeno-associated virus vector. Gene Ther (1994) 0.75
Isolation of a simian virus 40-simian agent 12 recombinant papovavirus that synthesizes a hybrid large tumour antigen. J Gen Virol (1988) 0.75
Methods for the construction and propagation of recombinant adeno-associated virus vectors. Methods Mol Med (1997) 0.75